Spironolactone Does Not Prevent Diabetic Nephropathy in Type 2 Diabetes
In a study, spironolactone treatment was not significantly better than placebo in preventing diabetic nephropathy in patients with high-risk type 2 diabetes.
Diabetic Nephropathy
Canagliflozin Protects Against Renal Function Decline in Advanced Diabetic CKD
WASHINGTON—Canagliflozin showed a protective effect against kidney function decline in patients with type 2 diabetes and a baseline estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2, new study findings presented at the American Society of Nephrology’s Kidney Week 2019 meeting suggest. The findings are from a post-hoc subgroup analysis of the phase 3 CREDENCE…
Aggressive Lowering of HbA1c in T1DM Does Not Reduce Eye, Kidney Disease
Sweden’s lower HbA1c target values not linked to further organ protection
FDA Approves Canagliflozin for Diabetic Kidney Disease
FDA’s approval of canagliflozin for slowing progression of diabetic nephropathy in patients with type 2 diabetes makes the drug the first new treatment option in nearly 20 years indicated for slowing diabetic kidney disease in these patients.
Metformin Superior for Lowering CV Risk in Diabetics Who Progress to CKD
Continued monotherapy with metformin, compared with a sulfonylurea, is associated with a lower risk for major adverse cardiovascular events (MACE) among patients with type 2 diabetes who experienced reduced kidney function.
Review: SGLT2 Inhibitors Provide Clear Renal Benefits in Type 2 Diabetes
New review identifies benefits of sodium-glucose co-transporter-2 (SGLT2) inhibitors at almost all levels of kidney function.
Machine Learning Algorithms Promising in Kidney Diagnostics
Machine learning algorithms can aid in assessment of renal histopathology
Periop Diabetic Ketoacidosis Seen in Patients on SGLT2 Inhibitors
Testing for acid load needed in patients with diabetes taking sodium-glucose cotransporter-2 inhibitors
Kidney Disease Care for Type 2 Diabetics: Dawn of a New Era?
Studies document renal benefits of canagliflozin, dapagliflozin, empagliflozin, and dulaglutide
Esaxerenone Improves Microalbuminuria in Type 2 Diabetes
In a phase 2 study of patients with early diabetic nephropathy, esaxerenone decreased microalbuminuria in a dose-dependent manner over 12 weeks compared with placebo.
-
Loading...
-
Loading...
Next post in Diabetic Nephropathy
